Alvotech (ALVO) Income from Continuing Operations (2021 - 2026)
Alvotech's (ALVO) quarterly Income from Continuing Operations came in at 79000.0 in Q1 2026, down 99.93% YoY from 109921000.0 in Q1 2025, and down 99.97% on a QoQ basis from 299898000.0 in Q4 2025.
Alvotech (ALVO) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Alvotech (ALVO) has 6 years of Income from Continuing Operations data on file, last reported at 79000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 99.93% year-over-year to 79000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26506000.0 (up 109.76% YoY) and the FY2025 annual result came in at 27919000.0, up 111.31% from the prior year.
- Income from Continuing Operations slipped to 79000.0 in Q1 2026, from 299898000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 299898000.0 in Q4 2025 to a low of 651135000.0 in Q4 2023.
- A 5-year average of 89142941.18 and a median of 275532.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 370.11% — and 2025, when it jumped 50166.73%.
- Tracing ALVO's Income from Continuing Operations over 5 years: stood at 557758000.0 in 2022, then decreased by 16.74% to 651135000.0 in 2023, then jumped by 66.48% to 218253000.0 in 2024, then jumped by 237.41% to 299898000.0 in 2025, then slumped by 99.97% to 79000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 79000.0 (Q1 2026), 299898000.0 (Q4 2025), and 308702000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alvotech | 1.26 Bn | 1.26 Bn | 5.09 Mn | 942,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79,000.00 |
| Dec 31, 2025 | 299.90 Mn |
| Sep 30, 2025 | -308.70 Mn |
| Jun 30, 2025 | 35.23 Mn |
| Mar 31, 2025 | 109.92 Mn |
| Dec 31, 2024 | -218.25 Mn |
| Sep 30, 2024 | -316.93 Mn |
| Jun 30, 2024 | 153.60 Mn |
| Mar 31, 2024 | -219,549.00 |
| Dec 31, 2023 | -651.14 Mn |
| Aug 31, 2023 | -136.71 Mn |
| Jun 30, 2023 | 88.65 Mn |
| Mar 31, 2023 | -275,532.00 |
| Dec 31, 2022 | -557.76 Mn |
| Aug 31, 2022 | -201.54 Mn |
| Jun 30, 2022 | 265.78 Mn |
| Mar 31, 2022 | -77.06 Mn |
| Dec 31, 2021 | 206.49 Mn |
| Sep 30, 2021 | -55.83 Mn |